Global Rare Kidney Diseases Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 8.1 Billion by the year 2034 at a 11.0% CAGR during the forecast period for 2025-2034.
Get A Free Report Brochure:
https://www.insightaceanalytic.com/request-sample/1414
Rare kidney diseases encompass a group of uncommon renal disorders that result in impaired kidney function, leading to toxin accumulation in the body and subsequent health complications. Many of these conditions have a genetic or hereditary origin and occur infrequently within the general population.
Key disorders in this category include Lupus Nephritis, Membranous Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy, and C3 Glomerulopathy. Among these, IgA Nephropathy is distinguished by the deposition of IgA antibodies in kidney tissues, which triggers inflammation and may progress to kidney failure.
List of Prominent Players in the Rare Kidney Diseases Market:
- GlaxoSmithKline,
- Recordati Rare Diseases,
- Amicus Therapeutics,
- Calliditas Therapeutics,
- Alexion Pharmaceuticals (A subsidiary of AstraZeneca),
- Travere Therapeutics,
- Aurinia Pharmaceutical,
- Advicenne,
- Protalix Biotherapeutics,
- AstraZeneca,
- Chinook Therapeutics,
- Reata Pharmaceuticals,
- Roche,
- Novartis Pharmaceuticals,
- Merk & co.,
- Apellis Pharmaceuticals,
- Omeros Corporation,
- Lonza
Market Dynamics:
Drivers-
The rare kidney disease market is experiencing substantial growth, driven by several key factors. One of the primary contributors is the expanding pipeline of innovative treatments, with over 21,630 participants currently enrolled in clinical trials assessing therapies at various developmental stages. The rising global prevalence of rare renal disorders has heightened the demand for advanced and effective treatment solutions, leading to increased investment in this sector.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1414
Challenges:
Despite advancements in research and drug development, several challenges continue to impede the growth of the rare kidney disease market. Research funding and healthcare systems tend to prioritize more prevalent diseases, often leaving rare kidney disorders underfunded and overlooked. Additionally, limited data availability on these conditions creates gaps in research, healthcare policies, and clinical care.
Regional Trends:
North America is expected to lead the rare kidney disease market, holding a significant revenue share and registering a high compound annual growth rate (CAGR) in the coming years. Several factors contribute to this regional dominance, including the increasing incidence of rare renal conditions such as Fabry disease, lupus nephritis, nephropathic cystinosis, and atypical hemolytic uremic syndrome. Furthermore, greater government and nonprofit funding for research, higher healthcare expenditures, early adoption of advanced technologies, and the widespread acceptance of innovative diagnostic and therapeutic solutions are expected to drive market growth in the region.
Recent Developments:
- In August 2023, Novartis completed the purchase of US clinical-stage biopharmaceutical company Chinook Therapeutics. Chinook Therapeutics develops kidney-specific drugs. An initial $3.2 billion payment was made, with a possible $3.5 billion purchase value.
- In March 2024, Travere Therapeutics, Inc. filed a sNDA to the FDA to convert FILSPARI® (sparsentan)’s expedited approval in IgAN to full approval. FILSPARI, the first and only non-immunosuppressive medication to treat kidney glomerular degeneration and proteinuria in primary IgAN patients at risk of fast disease progression, received expedited FDA clearance in February 2023.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1414
Segmentation of Rare Kidney Diseases Market-
By Target Indication-
- IgA Nephropathy
- Lupus Nephritis
- Focal Segmental Glomerular Sclerosis
- Membranous Nephropathy
- C3 Glomerulopathy
- Cystinosis
- Dense Deposit Disease
- Distal Renal Tubular Acidosis
- Fabry Disease
- Refractory Gout
- Atypical Hemolytic Uremic Syndrome
- Others
By Type of Molecule-
- Small Molecules
- Biologics
- Monoclonal Antibody
- Hormone
- Recombinant Protein
- Others
By Route of Administration-
- Oral
- Intravenous
- Subcutaneous
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More information: @
https://www.insightaceanalytic.com/report/global-rare-kidney-diseases-market-/1414
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
